Sign up for our Oncology Central weekly news round-up

Breakthrough targeted therapeutic approaches to squamous cell carcinoma of the head and neck


Head and neck squamous cell carcinoma (HNSCC) represents the vast majority (i.e., more than 90%) of head and neck tumors. Notably, HNSCC represents the sixth most common cancer worldwide and currently, for this tumor, an incidence of over 600,000 people per year is reported [1,2].

Outcome is age and stage related. In addition, 5-year survival rates superior to 54% for young patients (15–45 years of age) and of 35% for older patients (>75 years of age) have been reported [3]. Notably, despite the massive advances achieved over the last few years in HNSCC therapeutic management, for advanced stages of diease, the mortality rate is still very high.

Click here to view the full article